Eficold (paracetamol, caffeine) effervescent tablets 500 mg/50 mg. №32

$6.00

Manufacturer: Bulgaria

The drug has a moderate analgesic and antipyretic effect. Indications for use are headache, including migraine, toothache, neuralgia, rheumatic pain, periodic pain in women; used to relieve symptoms of colds and flu, sore throat.

Category:

Description

Eficold Storage
active substances: paracetamol, caffeine;

1 tablet contains paracetamol 500 mg and caffeine 50 mg;

Eficold excipients: sodium bicarbonate; citric acid anhydrous; sorbitol (E 420); lactose monohydrate; sodium saccharin; L-leucine; povidone.

Eficold Dosage form
Effervescent tablets.

Basic physical and chemical properties: round tablets of white color, with beveled edges, with a line on one side.

Pharmacotherapeutic group
Analgesics and antipyretics. Paracetamol, combinations without psycholeptics. ATX code N02B E51.

Pharmacological properties
Effervescent tablets of the drug combine the analgesic and antipyretic action of paracetamol with caffeine, which acts as an auxiliary analgesic substance.

Paracetamol has antipyretic and analgesic effects against moderate pain. It does not act on spasmodic pain and has no calming or psychodysleptic effect.

Caffeine is an adjuvant that enhances the analgesic effect of paracetamol. It also has a stimulating effect on the CNS.

Pharmacodynamics.

The analgesic effect of paracetamol is the result of central inhibition of the synthesis of prostaglandins and other pain mediators. Its antipyretic effect is due to inhibition of prostaglandin synthesis at the level of the thermoregulatory center of the hypothalamus, which causes dilation of peripheral blood vessels and lower skin temperature.

Caffeine has a stimulating effect on the CNS, mainly due to antagonism of adenosine receptors.

Pharmacokinetics.

Absorption of paracetamol is rapid and almost complete. Its half-life in blood plasma ranges from 1 to 4 hours; it does not change in renal failure, but may decrease in children or increase in case of overdose, liver disease and in elderly patients.

Plasma protein binding of paracetamol is low, but may be moderate at high or toxic doses.

Approximately 90-95% of the dose is metabolized in the liver under the influence of two types of metabolism.

The main type of metabolism is by conjugation to sulfate or glucuronic acid to form sulfate and glucuronide derivatives. On the other hand, a small proportion of paracetamol is converted by cytochrome P 450 to a highly reactive metabolite. At therapeutic doses, this metabolite is rapidly neutralized by conjugation to glutathione. The derivative conjugates are then excreted in the urine. 3% of the dose is excreted in the urine unchanged.

Caffeine is rapidly absorbed after oral administration. It is evenly distributed and quickly reaches the central nervous system. It is almost completely metabolized in the liver and then excreted mainly in the urine as 1-methylurea and

1-methylxanthine. About 1% of the dose is excreted unchanged in the urine.

The half-life of caffeine in blood plasma is from 3 to 7 hours.

Indication
The drug has a moderate analgesic and antipyretic effect. Indications for use are headache, including migraine, toothache, neuralgia, rheumatic pain, recurrent pain in women; used to relieve symptoms of colds and flu, sore throat.

Contraindication
Hypersensitivity to paracetamol, caffeine or to any other component of the drug in the anamnesis; severe liver and / or kidney disorders; congenital hyperbilirubinemia; glucose-6-phosphate dehydrogenase deficiency; fructose intolerance; alcoholism; blood diseases, severe anemia, leukopenia; states of heightened arousal, sleep disturbances, epilepsy; pronounced increase in blood pressure, organic diseases of the cardiovascular system, including severe atherosclerosis, severe hypertension; uncompensated heart failure, acute myocardial infarction; paroxysmal tachycardia, hyperthyroidism, acute pancreatitis, severe diabetes mellitus, glaucoma; age over 60 years.

Do not use together with monoamine oxidase (MAO) inhibitors and for 2 weeks after discontinuation of MAO inhibitors.

Contraindicated in patients taking tricyclic antidepressants or beta-blockers.